PerkinElmer's Horizon Discovery Says Extends Gene Modulation Portfolio With 'Industry First' Synthetic Single Guide RNA And Patent Pending dCas9 Repressor For CRISPR Interface
PerkinElmer's Horizon Discovery Says Extends Gene Modulation Portfolio With 'Industry First' Synthetic Single Guide RNA And Patent Pending dCas9 Repressor For CRISPR Interface
Horizon Discovery Extends Gene Modulation Portfolio with Industry First Synthetic Single Guide RNA and Patent Pending dCas9 Repressor for CRISPR Interference
Horizon Discovery推出业界首个合成单引导RNA和正在申请专利的用于CRISPR干扰的dCas9抑制物，扩大了基因调制产品组合
CRISPRi Innovations Provide Expanded Experimental Options and Flexibility For Researchers Facilitating Disease & Drug Research
CRISPRi创新为促进疾病和药物研究的研究人员提供了更多的实验选择和灵活性
Horizon Discovery, a PerkinElmer, Inc. (NYSE:PKI) company, today announced that its gene editing and modulation portfolio is expanding to include a new family of CRISPR modulation (CRISPRmod) reagents for CRISPR interference (CRISPRi). CRISPRi enables scientists to better understand the biological pathways, processes and pathologies of disease by repressing genes at the transcriptional level, ultimately leading to new therapeutic approaches.
地平线发现号，一部PerkinElmer公司*(纽约证券交易所：PKI)公司今天宣布，其基因编辑和调制产品组合正在扩大，包括一系列新的CRISPR调制(CRISPRmod)试剂，用于CRISPR干扰(CRISPRi)。CRISPRi使科学家能够通过在转录水平上抑制基因，更好地了解疾病的生物途径、过程和病理，最终导致新的治疗方法。
The new reagents include the first-ever commercially available synthetic single guide RNAs for CRISPRi, as well as a patent-pending, dCas9-SALL1-SDS3 repressor available in mRNA and lentiviral formats. With these new technologies, researchers will have the flexibility to repress genes in almost all cell lines, over any length of time, and at any scale from single gene readouts to high-throughput studies.
新试剂包括有史以来第一个商业化的试剂。针对CRISPRI的合成单导RNA，以及正在申请专利的dCas9-SALL1-SDS3抑制子。mrna和慢病毒各种格式。有了这些新技术，研究人员将可以灵活地抑制几乎所有细胞系中的基因，在任何时间段，从单基因读出到高通量研究的任何规模。
The novel dCas9-SALL1-SDS3 repressor was developed following extensive research and has shown more robust and consistent gene modulation over a longer course of time compared to current-generation CRISPRi products.
新的dCas9-SALL1-SDS3抑制子是经过广泛研究开发的，与当前一代的CRISPRi产品相比，它在更长的时间内显示出更强大和一致的基因调控。
Alan Fletcher, SVP Life Sciences at PerkinElmer said, "CRISPRi is gene knockdown, not knockout. It's CRISPR without the cut, so it offers a temporary and nuanced approach which is ideal for researchers looking to mimic cellular effects of small molecule drugs or do multiplexed gene interrogation. By offering these new reagents, in addition to our existing CRISPR options, we're primed to aid researchers in achieving even more exciting breakthroughs in the years ahead."
PerkinElmer生命科学高级副总裁艾伦·弗莱彻说：“CRISPRi是基因敲除，而不是敲除。它是一种没有切割的CRISPR，因此它提供了一种临时和细微差别的方法，对于希望模拟小分子药物的细胞效应或进行多路基因询问的研究人员来说，这是理想的。通过提供这些新试剂，加上我们现有的CRISPR选项，我们准备在未来几年帮助研究人员取得更令人兴奋的突破。”
Horizon Discovery's Dharmacon technology, with its patented siRNA tools, has been the market leader in gene modulation for more than 20 years. Since the discovery of CRISPR gene editing tools, Horizon has been on the forefront offering guide and nuclease products to enable precision DIY CRISPR knockout and knock-in as well as custom screening and cell line production services. CRISPRmod CRISPRi continues the tradition of innovation by developing novel CRISPR-based transcriptional gene modulation reagents. Portfolio-wide, Horizon helps researchers answer fundamental biological questions leading to therapeutic advancements.
Horizon Discovery的达哈纳康技术凭借其获得专利的siRNA工具，20多年来一直是基因调制领域的市场领先者。自从发现CRISPR基因编辑工具以来，Horizon一直走在前列，提供指南和核酸酶产品，实现精确的DIY CRISPR基因敲除和敲入，以及定制筛选和细胞系生产服务。CRISPRmod CRISPRi通过开发基于CRISPR的新型转录基因调制试剂，延续了创新的传统。在整个投资组合中，Horizon帮助研究人员回答导致治疗进步的基本生物学问题。
For further information on Horizon Discovery's CRISPRi technology, please visit: https://horizondiscovery.com/en/applications/crisprmod/crispri.
有关Horizon Discovery公司CRISPRi技术的更多信息，请访问：Https://horizondiscovery.com/en/applications/crisprmod/crispri。
About PerkinElmer
关于PerkinElmer
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at https://www.perkinelmer.com/.
PerkinElmer使科学家、研究人员和临床医生能够解决他们在科学和医疗保健领域面临的最严峻挑战。我们的使命是致力于为更健康的世界创新，我们提供独特的解决方案，服务于诊断、生命科学、食品和应用市场。我们与客户建立战略合作伙伴关系，以便在深厚的市场知识和技术专长的支持下，更早、更准确地洞察情况。我们在全球拥有约14,000名员工的敬业团队热忱地帮助客户创建更健康的家庭，提高生活质量，并维持全球人民的福祉和长寿。该公司2020年的收入约为38亿美元，服务于190个国家和地区的客户，是S指数的成分股。欲了解更多信息，请拨打电话1-877-PKI-NYSE，或登录：Https://www.perkinelmer.com/。
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005565/en/
在Business wire.com上查看源代码版本：Https://www.businesswire.com/news/home/20210329005565/en/
译文内容由第三方软件翻译。